Communiqués OnKure Therapeutics, Inc.

Actions

OKUR

US68277Q1058

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 20:14:53 30/09/2026			Varia. 5j.	Varia. 1 janv.
2,640 ^USD	+1,54%		-10,03%	-8,79%

14/08	OnKure Therapeutics, Inc. : Oppenheimer favorable sur le dossier	ZM
04/08	OnKure Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

31/08	OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference	AQ
04/08	OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights	AQ
02/07	OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026	AQ
05/05	OnKure Therapeutics Reports First Quarter 2026 Financial Results	AQ
27/03	OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies	AQ
12/03	OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results	AQ
06/11	OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update	AQ
04/11	OnKure Therapeutics to Participate in Upcoming Investor Conferences	AQ
12/08/25	OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update	AQ
06/05/25	OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights	AQ
10/03/25	OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights	AQ
04/03/25	OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences	AQ
11/12/24	OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic Data from its First-In-Human PIKture-01 Trial of OKI-219	AQ
10/12/24	OnKure Therapeutics : Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First In Human PIKture 01 Trial of OKI 219 Form 8 K	PU
10/12/24	OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219	AQ
25/11/24	OnKure Announces New Date for Upcoming Investor Call	AQ
07/11/24	OnKure Therapeutics : INDEX TO UNAUDITED CONDENSED FINANCIAL STATEMENTS Form 8 K	PU
05/11/24	OnKure to Present at the Stifel 2024 Healthcare Conference	AQ
01/11/24	OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium	AQ
08/10/24	ONKE THERPAR : Report of Independent Registered Public Accounting Firm Form 8 K	PU
04/10/24	OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million	GL
03/10/24	Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure	GL
29/08/24	RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM	BU
13/08/24	Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results	GL
15/05/24	RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM	BU